Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Rho-kinase inhibitors

a technology of rho-kinase and inhibitors, which is applied in the direction of biocide, drug composition, extracellular fluid disorder, etc., can solve the problem that diseases pose a serious unmet medical need

Inactive Publication Date: 2005-09-22
BAYER HEALTHCARE LLC
View PDF1 Cites 147 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes compounds that can be used to treat a variety of medical conditions such as hypertension, atherosclerosis, and erectile dysfunction. These compounds are Rho kinase inhibitors, which means they can help to relax the blood vessels and improve blood flow. The patent also explains how these compounds can be made using standard chemical methods. Overall, this patent provides a useful tool for researchers to develop new treatments for these medical conditions.

Problems solved by technology

These diseases pose a serious unmet medical need.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rho-kinase inhibitors
  • Rho-kinase inhibitors
  • Rho-kinase inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of N-(2-amino-6-methyl-4-pyrimidinyl)-N-[3-fluoro-4-(4-pyridinylsulfanyl)phenyl]amine

[0081]

[0082] A suspension of 2-amino-4-chloro-6-methylpyrimidine (Intermediate A7, 0.2 g, 1.3 mmol), 3-fluoro-4-(4-pyridinylthio)aniline (Intermediate B7, 0.3 g, 1.3 mmol), and K2CO3 (0.2 g, 1.3 mmol) in o-xylene (1.3 mL) was heated to 100° C. in a 5 mL reaction-vial overnight. The reaction mixture was diluted with MeOH and coated on silica and purified by MPLC (Biotage) with 5-7% MeOH in CH2Cl2. It afforded 74 mg of product (18% yield). TLC (6% MeOH / 94% CH2Cl2) Rf 0.29; MS ES 328 [M+H]+; 1H-NMR (DMSO-d6) δ 2.12 (s, 3H), 5.92 (s, 1H), 6.38 (bs, 2H), 6.96 (d, J=5.1 Hz, 2H), 7.39-7.52 (m, 2H), 8.26 (d, J=11.9 Hz, 1H), 8.33 (d, J=4.8 Hz, 2H), 9.55 (bs, 1H).

example 2

Preparation of 6-ethyl-N4-[3-fluoro-4-(4-pyridinylsulfanyl)phenyl]-2,4-pyrimidinediamine

[0083]

[0084] 2-Amino-4-chloro-6-ethylpyrimidine (Intermediate A8, 55.1 mg, 0.25 mmol) and Intermediate B7(39.4 mg, 0.25 mmol) were suspended in 0.01 M aqueous HCl (500 μL). The mixture was refluxed for 6 h. The reaction was cooled to room temperature and the solvent was evaporated by vacuum. The residue was purified by reversed phase chromatography on a YMC Pack-pro C18 column (trademark) eluting with acetonitrile / H2O (10:90-90:10 gradient). The compound was further purified by preparative TLC eluting with CH2Cl2-MeOH (90: 10). Desired compound (2.9 mg, 0.0085 mmol; 34% yield); 1H NMR (Methanol-d4) 8.16 (dd, J=1.7, 4.7, 2H), 8.00-8.04 (m, 1H), 7.37 (m, 2H), 6.93 (dd, J=1.8, 4.9, 2H), 5.91 (s, 1), 2.39 (q, J=7.7, 2H), 1.13 (t, J=7.5, 3H); ES MS [M+H]+=342 ; TLC (CH2Cl2-MeOH, 90:10); Rf =0.48.

examples 3-26

[0085] Using the above procedures, the following examples of pyridines were synthesized and are summarized in Table 3.

TABLE 3IaIntermediateIntermediatePyrimidoneAmineEx. No.(A)(B)R1R2R4Analytical Data3A9B1HHamp = 245-247°C.; 1H NMR (Methanol-d4)8.79 (d, J = 5.7, 2H), 8.32 (s, 1H), 8.13 (d, J =5.9, 2H), 7.97 (d, J = 9.2, 1H), 7.88 (d, J =3.6, 1H), 7.71 (d, J = 7.3, 1H), 7.56 (d, J =9.1, 1H), 6.94 (d, J = 4.0, 1H), 6.33 (d, J =7.6, 1H); ES MS [M + H]+ = 303.4A1B1CH3CH2—Hamp = 230-233° C.; 1H NMR (DMSO-d6)12.43 (s, 1H), 10.51 (s, 1H), 8.79 (d, J = 6.3,2H), 8.22 (s, 1H), 7.87-8.23 (m, 5H), 7.46(d, J = 8.4, 1H), 6.85 (d, J = 3.3, 1H), 6.14 (s,1H), 2.51-2.61 (m, 2H), 1.19 (t, J = 7.5,3H); ES MS [M + H]+ 331.5A1B1CH3—Clamp = 238-241° C.; ES MS [M + H]+ = 351;TLC: Rf = 0.71 (CH2Cl2-MeOH, 95:5).6A1B1—(CH2)4—a1H NMR(DMSO-d6) 11.75 (s, 1H), 10.59 (s,1H), 8.78 (d, J = 5.4, 2H), 8.21 (s, 1H), 7.87-7.97 (m, 5H), 7.47 (d, J = 8.1, 1H), 6.85 (d,J = 3.4, 1H), 6.21 (s, 1H), 1.29 (s, 9H); ESMS [M + ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
timeaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.

Description

FIELD OF THE INVENTION [0001] The present invention relates to compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease. BACKGROUND [0002] The pathology of a number of human and animal diseases including hypertension, erectile dysfunction, coronary cerebral circulatory impairments, neurodegenerative disorders and cancer can be linked directly to changes in the actin cytoskeleton. These diseases pose a serious unmet medical need. The actin cytoskeleton is composed of a meshwork of actin filaments and actin-binding proteins found in all eukaryotic cells. In smooth muscle cells the assembly and disassembly of the actin cytoskeleton is the primary motor force responsible for smooth muscle contraction and relaxation. In non-muscle cells, dynamic rearrangements ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/505A61K31/506C07D239/48A61K31/517A61P7/02A61P9/00A61P9/10A61P9/12A61P11/06A61P15/10A61P19/10A61P25/00A61P25/06A61P25/28A61P27/06A61P35/00A61P43/00C07D401/12C07D401/14
CPCC07D401/14C07D401/12A61P11/06A61P15/00A61P15/10A61P19/08A61P19/10A61P25/00A61P25/06A61P25/28A61P27/06A61P35/00A61P43/00A61P7/02A61P9/00A61P9/10A61P9/12
Inventor NAGARATHNAM, DHANAPALANDUMAS, JACQUESHATOUM-MOKDAD, HOLIABOYER, STEPHENPLUEMPE, HANS
Owner BAYER HEALTHCARE LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com